Early vs. Delayed CABG

Overview

Terminology

Key Evidence

Meta-Analysis: CABG Timing in AMI (Lang et al., 2022 — PMID 35419440)

• CABG within 24h vs. after 24h (all-AMI): OR for in-hospital mortality 2.65 (95% CI 1.96–3.58; p<0.00001) — strongly favoring delay
• STEMI subgroup: OR 2.62 (95% CI 1.58–4.35; p=0.0002) — early CABG significantly worse
• NSTEMI subgroup: OR 1.24 (95% CI 0.83–1.85; p=0.29) — no significant mortality difference between early and delayed CABG
• CABG within 48h vs. after 48h: OR 1.91 (95% CI 1.11–3.29; p=0.02) — still favors later timing
• Perioperative MI and stroke rates did not differ significantly between early and late groups

National Cohort Analysis (Hadaya et al., 2022 — PMID 34126075)

• Costs at days 4–7 were $6,400 higher than days 1–3; costs >7 days were $21,200 higher
• High-performing hospitals had median time to CABG of 2 days — and mortality of 0.9% vs 3.3% at other hospitals
• Practical takeaway: Days 1–3 appears to be the optimal window, balancing mortality and cost

Context-Specific Guidance

STEMI

• Primary PCI is preferred; CABG is reserved for failed PCI, complex anatomy unsuitable for PCI, mechanical complications (e.g., acute VSD, papillary muscle rupture), or significant left main/3-vessel disease
• When CABG is required post-STEMI, guidelines and evidence support delaying at least 24–48 hours after infarct stabilization unless emergent indication exists
• Cardiogenic shock remains a class I indication for immediate revascularization (surgical or percutaneous)

NSTEMI / Unstable Angina

• CABG timing is more flexible — meta-analysis shows no mortality difference between early and late surgery
• Earlier surgery (days 1–3) is often favored to reduce length of stay and cost without incremental mortality risk
• Antiplatelet washout periods must be factored in (see below)

Multivessel Disease / Diabetes

• CABG offers superior outcomes over PCI for 3-vessel disease and left main disease, particularly with diabetes and higher SYNTAX scores
• These patients often benefit from CABG even in the ACS setting, with timing guided by hemodynamic stability

Antiplatelet Washout: A Key Determinant of CABG Timing

Summary: Decision Framework

ACS patient requiring CABG
        │
        ├── Hemodynamically unstable / cardiogenic shock / failed PCI
        │        └── EMERGENT CABG (same day) — accept higher mortality risk
        │
        ├── STEMI, hemodynamically stable
        │        └── DELAY ≥24–48h; optimal ~1–3 days after stabilization
        │
        ├── NSTEMI / UA, stable
        │        └── Days 1–3 preferred (lowest mortality + cost)
        │                  → Must account for antiplatelet washout
        │
        └── Elective multi-vessel disease
                 └── >7 days confers no mortality benefit and raises costs

Recent Review Highlight (2024)

• PCI is generally preferred for timeliness in high-risk NSTE-ACS
• CABG offers superior cardiovascular outcomes in multivessel disease + diabetes or high SYNTAX score
• Optimal antiplatelet therapy post-CABG remains controversial (DAPT reduces ischemic events but increases bleeding)